Biomica Reports Positive Preliminary Results in Animal Studies in its Immuno-Oncology Program

Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127

Rehovot, Israel – November 12, 2019 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today positive preliminary results from recently completed animal studies in its immuno-oncology program,

Biomica Announces the Addition of Internationally Renowned Experts in the Fields of Gastroenterology and the Human Microbiome to its Scientific Advisory Board

This addition to Biomica’s scientific expertise will support the company’s upcoming steps towards its clinical development

Rehovot, Israel – 06 November, 2018 – Biomica, a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics announced today that internationally renowned experts have joined the company’s scientific advisory board.

Biomica, Evogene’s Newly Established Subsidiary, Announces Therapeutic Areas of Focus

Biomica leverages proprietary Computational Predictive Biology platform tailored to develop human microbiome therapies for antibiotic resistant bacteria, Immuno-Oncology and GI related disorders

Rehovot, Israel – 01 May, 2018 –Biomica, a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene’s Computational Predictive Biology (CPB) platform,